Alternatives to Deep 6 AI

AI foundation models predicting patient drug response to de-risk clinical trials

AI-powered patient identification for clinical trials — daily EHR scans, email alerts for eligible patients.

Clinical trial matching for physicians, built into their workflow.

AI-driven health data platform uniting patient care and clinical research

End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.

Oncology real-world evidence platform turning patient data into AI-powered insights for cancer research and care.

AI-powered precision oncology platform analyzing clinical and molecular data for personalized cancer care.

AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies

AI agents for quantitative clinical trial design and evidence synthesis

Domain-specific clinical data and RL environments for healthcare AI

AI real-world evidence generation from clinical data in minutes

AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.

AI-powered clinical trial recruitment and real-world data from EHR

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data.

Causal AI for human health, turning 20+ petabytes of cellular data into targeted therapeutics.

ML-guided protein engineering platform for multi-property co-optimization with compounding models from your own experimental data

Agentic AI for multimodal R&D data analysis and workflow automation

AI-driven drug discovery platform combining 50+ PB of proprietary data with automated wet labs to design and validate optimized molecules.

AI data analyst for bio labs: raw data to publication-ready results

Open-source automated model assembly from literature and databases for systems biology

Owkin's K Pro: an autonomous AI scientist for biopharma R&D decision-making

Tech-driven drug discovery and biologics manufacturing platform

Mechanistic interpretability platform to understand, debug, and design AI models

Highly selective small-molecule drug discovery for oncology, immunology, and metabolic diseases.

All-in-human AI foundation models for precision neurology and CNS drug discovery

Generative AI and robotics for autonomous drug discovery, compressing the DMTA cycle to under two years.

Physics-based molecular discovery platform for drug and materials design

FDA-cleared AI for cancer pathology diagnostics and biomarker discovery.

Regulatory-cleared quantitative imaging biomarkers from MRI, CT, and PET for radiology and biopharma

AI-driven biomanufacturing for personalized stem cell therapies